When will the patents on ACHROMYCIN V expire, and when will ACHROMYCIN V go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avet	ACHROMYCIN V	tetracycline hydrochloride	CAPSULE;ORAL	050278-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Avet	ACHROMYCIN V	tetracycline hydrochloride	CAPSULE;ORAL	050278-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lederle	ACHROMYCIN V	tetracycline hydrochloride	SUSPENSION;ORAL	050263-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Executive Summary

Achromycin V, the brand name for tetracycline hydrochloride, is an established broad-spectrum antibiotic. Its market presence is characterized by generic competition and the expiration of primary patents. This analysis examines the current patent landscape, regulatory status, and market dynamics to assess the investment viability of Achromycin V. The drug’s foundational patents have long expired, leaving its commercialization reliant on manufacturing process patents and formulation innovations. Competition from newer antibiotic classes and the rise of antibiotic resistance present significant market challenges. Investment opportunities are likely limited to niche applications, generic manufacturing efficiency improvements, or the development of novel delivery systems.

What is Achromycin V and its Current Market Position?

Achromycin V is a tetracycline antibiotic. Tetracycline hydrochloride, the active pharmaceutical ingredient (API), was first introduced in the 1950s. It functions by inhibiting bacterial protein synthesis, targeting the 30S ribosomal subunit. Achromycin V is indicated for a range of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and certain sexually transmitted diseases.

The drug's historical significance is marked by its broad spectrum of activity against Gram-positive and Gram-negative bacteria. However, its market position today is predominantly that of a legacy drug. The vast majority of patents covering the composition of matter for tetracycline hydrochloride expired decades ago. Consequently, the market is saturated with generic versions from numerous manufacturers. This intense generic competition has driven down prices and significantly reduced profit margins for the original innovator and subsequent manufacturers.

Brand name recognition for Achromycin V persists in some markets due to historical usage and physician familiarity. However, clinical practice increasingly favors newer antibiotic classes due to concerns about side effects, resistance patterns, and improved efficacy profiles of newer agents. The emergence of tetracycline-resistant bacterial strains further limits its utility in certain therapeutic areas.

What is the Patent Status of Achromycin V?

The foundational patents for tetracycline and its hydrochloride salt have long expired. The original patents filed by Lederle Laboratories (later acquired by Pfizer) would have expired by the mid-1970s, assuming the maximum patent term for the era.

Current patent activity related to tetracycline hydrochloride primarily focuses on:

Manufacturing Processes: Patents may exist for novel or improved methods of synthesizing tetracycline hydrochloride, aiming for higher yields, lower impurity profiles, or more cost-effective production. These process patents can provide a competitive advantage to manufacturers who hold them, even if the API itself is off-patent.
Formulations and Delivery Systems: Innovations in drug delivery, such as extended-release formulations, topical applications, or combination therapies, could be subject to patent protection. These patents aim to improve patient compliance, enhance efficacy, or reduce side effects. For instance, patents might cover specific excipients, coatings, or drug-release mechanisms designed to optimize the therapeutic profile of tetracycline.
New Indications or Combinations: While less common for such an old drug, patents could theoretically be sought for novel uses of tetracycline hydrochloride or its combination with other active agents for specific therapeutic purposes. However, such claims would require substantial evidence of efficacy and non-obviousness compared to existing treatments.

A comprehensive review of patent databases (e.g., USPTO, EPO, WIPO) reveals a consistent stream of patents related to tetracycline synthesis and derivatives, but very few recent patents that would grant market exclusivity on the core tetracycline hydrochloride API itself. The focus has shifted from composition of matter to incremental improvements in production and delivery.

What are the Key Regulatory Considerations for Achromycin V?

Achromycin V, as tetracycline hydrochloride, is a well-established drug with a long history of regulatory approval worldwide. Its regulatory status is characterized by:

Approved Indications: The drug has been approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for a defined set of bacterial infections. These approved indications are based on clinical trials conducted when the drug was initially developed.
Generic Drug Approvals: Due to the expiration of primary patents, numerous generic versions of tetracycline hydrochloride have received Abbreviated New Drug Application (ANDA) approval in the United States and similar marketing authorizations in other regions. This signifies that generic manufacturers have demonstrated bioequivalence to the reference listed drug.
Post-Marketing Surveillance: Like all approved drugs, Achromycin V is subject to ongoing pharmacovigilance. Regulatory agencies monitor for adverse events and drug safety issues. Any new safety concerns could lead to label changes, restrictions, or, in rare cases, withdrawal from the market.
Antibiotic Stewardship Programs: Global initiatives promoting antibiotic stewardship can impact the prescribing patterns of older antibiotics like tetracycline. These programs encourage the judicious use of antibiotics to combat antimicrobial resistance, potentially leading to a decrease in the overall prescription volume of drugs like Achromycin V, especially for broad-spectrum empirical treatment.
Manufacturing Standards: Manufacturers of Achromycin V, whether for branded or generic products, must adhere to Current Good Manufacturing Practices (cGMP) as enforced by regulatory bodies. This ensures the quality, safety, and efficacy of the drug product.

The regulatory pathway for Achromycin V is mature. For new entrants, the primary regulatory hurdle would be the ANDA approval process, demonstrating bioequivalence to an existing approved generic. Innovation in formulations or indications would necessitate a more extensive regulatory review, potentially involving new clinical trials.

What are the Competitive and Market Dynamics for Achromycin V?

The competitive landscape for Achromycin V is highly fragmented and primarily dominated by generic manufacturers. Key market dynamics include:

Intense Generic Competition: The expiration of composition of matter patents has led to widespread generic availability. This has resulted in significant price erosion, making it difficult for any single manufacturer to command a high market share or premium pricing.
Competition from Newer Antibiotics: The development of newer antibiotic classes with improved efficacy, better safety profiles, and narrower spectrums of activity has displaced tetracycline in many treatment guidelines. For example, fluoroquinolones, macrolides, and cephalosporins are often preferred for certain infections.
Antimicrobial Resistance: The growing problem of antibiotic resistance is a significant factor. Resistance to tetracycline has emerged in many bacterial species, reducing its clinical effectiveness for infections that were once readily treatable. This drives a need for more potent or targeted antibiotics.
Niche Applications: Despite the broader challenges, Achromycin V may retain utility in specific niche applications. This can include treatment of certain specific infections where it remains effective and cost-efficient, or in regions where access to newer, more expensive antibiotics is limited. It also finds use in veterinary medicine.
Cost-Effectiveness: In certain markets, particularly low- and middle-income countries, the low cost of generic tetracycline hydrochloride can make it a viable treatment option where more expensive alternatives are not accessible.
Supply Chain and Manufacturing Efficiency: Competition among generic manufacturers often centers on manufacturing efficiency, supply chain reliability, and cost of goods. Companies with optimized production processes or strong raw material sourcing can gain a competitive edge.

The overall market for Achromycin V is mature and likely experiencing declining volumes in developed markets due to the factors above. Growth, if any, would be found in specific geographic regions or highly specialized formulations.

What are Potential Investment Scenarios for Achromycin V?

Given the mature market and generic competition, direct investment in the branded Achromycin V product is generally not advisable for significant growth. However, several niche investment scenarios could be considered:

Generic Manufacturing Optimization: Investment in companies that possess highly efficient, low-cost manufacturing processes for tetracycline hydrochloride API. This could involve patents on novel synthesis routes, purification techniques, or waste reduction methods. The focus would be on being a low-cost producer to serve the global generic market.
- Example: Acquiring or investing in a company with proprietary continuous manufacturing technology for tetracycline hydrochloride, reducing batch processing costs and improving scalability.
Novel Formulation Development: Investing in research and development for new formulations or delivery systems of tetracycline hydrochloride. This could aim to:
- Improve patient compliance (e.g., once-daily extended-release oral formulations).
- Target specific tissues or locations for localized treatment (e.g., advanced topical formulations for dermatological conditions).
- Develop combination therapies where tetracycline is a component with a synergistic effect with another agent.
- Example: A venture capital investment in a biotech startup developing a novel liposomal encapsulation method for topical tetracycline to enhance skin penetration and reduce systemic absorption for acne treatment.
Niche Market Penetration: Targeting specific geographic markets or therapeutic areas where Achromycin V retains significant utility and faces less competition. This requires in-depth regional market analysis and understanding of local prescribing patterns and regulatory environments.
- Example: A strategic acquisition of a generic pharmaceutical company with established distribution networks and marketing rights for tetracycline hydrochloride in emerging markets in Southeast Asia or Africa.
Veterinary Applications: Investigating and potentially investing in the development or marketing of tetracycline hydrochloride specifically for veterinary uses. The regulatory pathways and competitive landscape in veterinary medicine can differ significantly from human medicine.
- Example: A private equity firm acquiring a portfolio of veterinary pharmaceuticals that includes tetracycline-based products, aiming to expand their reach in livestock health.
API Supply Chain Consolidation: Investing in companies that control critical raw material inputs for tetracycline hydrochloride production or have established robust, resilient global supply chains. This provides a foundational element for any manufacturer.

The overarching theme for investment in Achromycin V is not growth of the drug's core market but rather leveraging existing infrastructure, manufacturing efficiencies, or developing incremental innovations that create new, albeit smaller, market opportunities.

Key Takeaways

Achromycin V (tetracycline hydrochloride) is a mature antibiotic with expired core composition of matter patents, leading to intense generic competition and price erosion. Its market position is challenged by newer antibiotic classes and the rise of antimicrobial resistance. Investment opportunities are limited to areas such as manufacturing process optimization, novel formulation development, niche market penetration (geographic or therapeutic), or veterinary applications. Companies with proprietary manufacturing technologies, innovative delivery systems, or strong positions in specific emerging markets may offer viable investment prospects.

Frequently Asked Questions

Are there any active patents that could block generic production of Achromycin V? No, the foundational patents for tetracycline hydrochloride as a composition of matter have long expired, allowing for generic production. However, patents on specific manufacturing processes or novel formulations could potentially impact individual generic manufacturers or products.
What is the primary reason for the decline in Achromycin V's market share in developed countries? The decline is primarily due to the development and adoption of newer antibiotic classes offering improved efficacy, better safety profiles, and narrower spectrums of activity. Additionally, the increasing prevalence of antibiotic resistance has limited its clinical utility.
Could Achromycin V be repurposed for new indications? While theoretically possible, repurposing such an old and well-studied drug for significant new indications would require substantial clinical evidence of efficacy and safety, demonstrating a clear advantage over existing treatments. Such efforts are rare for established antibiotics in the current pharmaceutical development landscape.
What are the main risks associated with investing in a company producing generic Achromycin V? The primary risks include extreme price competition leading to low profit margins, potential for supply chain disruptions, increasing regulatory scrutiny on antibiotic usage, and the ongoing threat of antibiotic resistance rendering the drug less effective.
Is Achromycin V still relevant in the treatment of common bacterial infections? Achromycin V remains relevant for certain specific infections and in particular geographic regions where newer, more expensive antibiotics are not readily available or cost-prohibitive. However, its role in empirical treatment of common infections in developed nations has diminished due to resistance and the availability of preferred alternatives.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website for Orange Book] [2] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from [EMA website] [3] World Intellectual Property Organization. (n.d.). Patentscope Database. Retrieved from [WIPO Patentscope website] [4] U.S. Patent and Trademark Office. (n.d.). Patent Public Search Database. Retrieved from [USPTO Patent Public Search website] [5] World Health Organization. (2015). Global Action Plan on Antimicrobial Resistance 2015-2030. Retrieved from [WHO website]

ACHROMYCIN V Drug Patent Profile

Which patents cover Achromycin V, and when can generic versions of Achromycin V launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Achromycin V

AI Deep Research

Questions you can ask:

Summary for ACHROMYCIN V

US Patents and Regulatory Information for ACHROMYCIN V

ACHROMYCIN V: Patent Landscape and Investment Viability Analysis